Please login to the form below

Not currently logged in
Email:
Password:

Hepatitis B virus

This page shows the latest Hepatitis B virus news and features for those working in and with pharma, biotech and healthcare.

First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India

First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India

Candidate uses similar technology from a licensed Hepatitis B vaccine. The first patients have been dosed with a novel virus-like particle vaccine targeting COVID-19 in a trial co-led ... The vaccine candidate was developed using SpyBiotech’s SpyCatcher

Latest news

  • GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2 GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2

    GlaxoSmithKline has announced positive results from a phase 2a study of its Ionis-partnered antisense medicine for chronic hepatitis B virus (CHB) infection. ... The drug, GSK3228836, showed marked reductions in hepatitis surface antigen (HBsAg) and

  • China backs use of Roche’s Actemra for coronavirus China backs use of Roche’s Actemra for coronavirus

    almost 3, 200 lives out of more than 93, 000 cases, 80, 000 of them within China where the virus is thought to have originated. ... The two companies are already working together on RNAi drugs against hepatitis B virus.

  • Gilead claims FDA okay for Descovy as second PrEP option Gilead claims FDA okay for Descovy as second PrEP option

    warning that patients with HIV and hepatitis B virus (HBV) co-infections can experience exacerbation when stopping treatment with the drug.

  • Arbutus hit hard as new hep B drug fails on safety Arbutus hit hard as new hep B drug fails on safety

    Shares have fallen sharply since company reported results. Shares in Arbutus have fallen sharply after the company reported that its hepatitis B virus (HBV) drug AB-506 has been abandoned. ... With chronic hepatitis C virus (HCV) infections now

  • GSK to develop Ionis hepatitis B drugs GSK to develop Ionis hepatitis B drugs

    GlaxoSmithKline has exercised its option to license Ionis' antisense medicines for chronic hepatitis B virus (CHB) infection, boosting its presence in virology. ... cancer. Current treatments for patients with CHB provide low levels of hepatitis B virus

More from news
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    hepatitis B virus (HBV). Strategic. collaboration ‐. development. $445m. Innate Pharma/. ... The agreement is for the development of therapies to eliminate the hepatits B virus (HBV) in vivo using the genome editing platform ARCUS.  Development will

  • Pharma deals in April 2015 Pharma deals in April 2015

    its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers. ... These are key markets for this product as more than 75% of all HCC cases occur in the APAC region, largely in association with

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

The other side of … Crohn’s disease
What patients say is their truth about living with chronic conditions. “I want to believe in my doctor but I feel more comfortable getting my guidance elsewhere.”...
OPEN Health brings the Best of Both Worlds to MAPS EMEA 2020
...
1000 Voices Survey
The patient voice is key to creating meaningful changes in healthcare; to drive patients to be more actively involved in their care, which leads to better outcomes. So, we went...

Infographics